Your browser doesn't support javascript.
loading
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
Absenger, G; Benhaim, L; Szkandera, J; Zhang, W; Yang, D; Labonte, M J; Pichler, M; Stotz, M; Samonigg, H; Renner, W; Gerger, A; Lenz, H-J.
Afiliação
  • Absenger G; 1] Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria [2] Research Unit Genetic Epidemiology and Pharmacogenetics, Medical University of Graz, Graz, Austria.
  • Benhaim L; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Szkandera J; 1] Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria [2] Research Unit Genetic Epidemiology and Pharmacogenetics, Medical University of Graz, Graz, Austria.
  • Zhang W; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Yang D; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Labonte MJ; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Pichler M; Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Stotz M; 1] Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria [2] Research Unit Genetic Epidemiology and Pharmacogenetics, Medical University of Graz, Graz, Austria.
  • Samonigg H; Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Renner W; 1] Research Unit Genetic Epidemiology and Pharmacogenetics, Medical University of Graz, Graz, Austria [2] Clinical Institute of Medical and Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
  • Gerger A; 1] Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria [2] Research Unit Genetic Epidemiology and Pharmacogenetics, Medical University of Graz, Graz, Austria.
  • Lenz HJ; 1] Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA [2] USC Center for Molecular Pathways and Drug Discovery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Pharmacogenomics J ; 14(2): 130-4, 2014 Apr.
Article em En | MEDLINE | ID: mdl-23567490
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimioterapia Adjuvante / Ciclina D1 / Fluoruracila Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Pharmacogenomics J Assunto da revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Áustria
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimioterapia Adjuvante / Ciclina D1 / Fluoruracila Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Pharmacogenomics J Assunto da revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Áustria